Results 181 to 190 of about 55,011 (304)

Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis [PDF]

Deep Dutta, Lakshmi Nagendra, Beatrice Anne, M. Kumar, Meha Sharma, A B Kamrul-Hasan   +5 more
openalex   +1 more source

Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices. [PDF]

ESC Heart Fail
Ibrahim R, Nhat H, Abdelnabi M, Forst B, Allam M, Mee XC, Lim GK, Bcharah G, Barry T, Farina J, Ayoub C, Arsanjani R, Lee K.   +12 more
europepmc   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review

Matt Thomas, Svetlana Mastitskaya, Samuel Parker, Ruth Cookson, Lucy Holmes, Aidan Marsh, Aravind Ramesh, Sarah Rudd, Mario Teo, Alex Mortimer   +9 more
openalex   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source

Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet–induced Mouse Model

Huimin Xia, Yuqin Min, Yuhua Wang, Siyu Gao, Hailing Wang, Fuhua Yan, Ruixin Liu, Jiqiu Wang, Xuejiang Gu, Tingting Bo   +9 more
openalex   +1 more source

A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus

, 2017
Hannah Botfield, Maria Uldall, Connar Stanley James Westgate, James Mitchell, Snorre Malm Hagen, Ana María Gonzalez, David J. Hodson, Rigmor Jensen, Alexandra J. Sinclair   +8 more
openalex   +2 more sources

Seizure recurrence after GLP‐1 receptor agonist initiation in adults with epilepsy

Epilepsia, EarlyView.
Abstract Objective To examine whether initiation of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) is associated with seizure recurrence and related outcomes in adults with epilepsy and type 2 diabetes. Methods We conducted a retrospective cohort study using de‐identified electronic health records from the TriNetX Research Network (January 2003 ...
Majd A. AbuAlrob, Abdullah Hussein, Rand Abdellatif, Adham Itbaisha, Khaled Zammar, Boulenouar Mesraoua   +5 more
wiley   +1 more source

A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db / db mice

, 2007
Desu Chen, Jiayu Liao, Na Li, Caihong Zhou, Qing Liu, Guangxing Wang, Rui Zhang, Song Zhang, Lilin Lin, Kaixian Chen, Xin Xie, Fajun Nan, Andrew A. Young, Ming‐Wei Wang   +13 more
openalex   +1 more source

The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome. [PDF]

JACC Adv
Kumar S, Anderson JE, Coviello A, Lopez-Jimenez F, Bakris GL.   +4 more
europepmc   +1 more source